Soil Moisture and Permittivity Estimation

The soil moisture and permittivity estimation is vital for the success of the variable rate approaches in the field of the decision agriculture. In this chapter, the development of a novel permittivity estimation and soil moisture sensing approach is presented. The empirical setup and experimental methodology for the power delay measurements used in model are introduced. Moreover, the performance analysis is explained that includes the model validation and error analysis. The transfer functions are reported as well for soil moisture and permittivity estimation. Furthermore, the potential applications of the developed approach in different disciplines are also examined

Signals in the Soil: An Introduction to Wireless Underground Communications

In this chapter, wireless underground (UG) communications are introduced. A detailed overview of WUC is given. A comprehensive review of research challenges in WUC is presented. The evolution of underground wireless is also discussed. Moreover, different component of UG communications is wireless. The WUC system architecture is explained with a detailed discussion of the anatomy of an underground mote. The examples of UG wireless communication systems are explored. Furthermore, the differences of UG wireless and over-the-air wireless are debated. Different types of wireless underground channel (e.g., In-Soil, Soil-to-Air, and Air-to-Soil) are reported as well

Iron Behaving Badly: Inappropriate Iron Chelation as a Major Contributor to the Aetiology of Vascular and Other Progressive Inflammatory and Degenerative Diseases

The production of peroxide and superoxide is an inevitable consequence of aerobic metabolism, and while these particular "reactive oxygen species" (ROSs) can exhibit a number of biological effects, they are not of themselves excessively reactive and thus they are not especially damaging at physiological concentrations. However, their reactions with poorly liganded iron species can lead to the catalytic production of the very reactive and dangerous hydroxyl radical, which is exceptionally damaging, and a major cause of chronic inflammation. We review the considerable and wide-ranging evidence for the involvement of this combination of (su)peroxide and poorly liganded iron in a large number of physiological and indeed pathological processes and inflammatory disorders, especially those involving the progressive degradation of cellular and organismal performance. These diseases share a great many similarities and thus might be considered to have a common cause (i.e. iron-catalysed free radical and especially hydroxyl radical generation). The studies reviewed include those focused on a series of cardiovascular, metabolic and neurological diseases, where iron can be found at the sites of plaques and lesions, as well as studies showing the significance of iron to aging and longevity. The effective chelation of iron by natural or synthetic ligands is thus of major physiological (and potentially therapeutic) importance. As systems properties, we need to recognise that physiological observables have multiple molecular causes, and studying them in isolation leads to inconsistent patterns of apparent causality when it is the simultaneous combination of multiple factors that is responsible. This explains, for instance, the decidedly mixed effects of antioxidants that have been observed, etc...Comment: 159 pages, including 9 Figs and 2184 reference

The Effectiveness of a Pram-Walking Exercise Programme in Reducing Depressive Symptomatology for Postnatal Women

The purpose of the research project was to examine the effects of exercise, social support and depression on postnatal women who reported experiencing Postnatal Depression (PND). A 12 week randomised controlled trial was conducted investigating the effects of an exercise intervention group (3 sessions/wk of 60%-75% intensity) compared to a social support group (1 session/wk). Participants in both groups had given birth in the past 12 months and were experiencing depressive symptomatology. Pre-test data of physical fitness and structured questionnaires were compared to post-test effects. The exercise intervention consisted of a pram walking program for mothers and their babies and the social support intervention involved non-structured sessions, similar to a play group. The primary outcomes were to reduce the depressive syptomatology and improve fitness levels of participants in the pram walking group. Secondary outcomes were to improve the social support levels of the participants in both groups and explore women's views about the programs. It was hypothesised that the pram walking group would improve their feelings of depression and fitness levels compared to the social support group, but that both groups would improve their perceived levels of social support. The results showed that mothers in the pram walking intervention group improved their fitness levels (VO2 max = p 0.05). These results are encouraging and suggest that a pram walking intervention has the potential to improve depressive symptomatology and fitness levels for women who reported experiencing postnatal depression. Therefore, a direct association between improvement in fitness was related to improvement in depression for the pram walking group. However, it is also suggested that other factors in combination with improvements in fitness influenced improvements in depressive levels. Tailored pram walking programs have the potential to provide primary and secondary treatment options for postnatal women. It is a recommendation that pram walking programs for mothers with PND be implemented as pilot research into existing available services. These conclusions and recommendations are tentative and could be confirmed with larger studies with larger cohorts

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy

Successful advances in the treatment of advanced malignant diseases rely on recruitment of patients into clinical trials of novel agents. However, there is a genuine concern for the welfare of individual patients. The aim of this study was to examine motives of patients entering early clinical trials of novel cancer therapies. Questionnaire survey with both open- and close-ended questions. The patients were surveyed after they had given informed consent and before or during the first cycle of treatment. In all, 38 phase I/II trial patients participated and completed the survey. Obtaining possible health benefit was listed by 89% as being a 'very important' factor in their decision to participate, with only 17% giving reasons of helping future cancer patients and treatment. Other items cited as a 'very important' motivating factor were 'trust in the doctor' (66%), 'being treated by the latest treatment available' (66%), 'better standard of care and closer follow-up' (61%), and 'closer monitoring of patients in trials' (58%). Only 47% patients indicated that someone had explained to them about any 'reasonable' alternatives to the trial. In total, 71% strongly agreed that 'surviving for as long time as possible was the most important thing (for them)'. Nearly all (97%) indicated that they knew the purpose of the trial and had enough time to consider participation in the trial (100%). In this survey, most patients entering phase I and II clinical trials felt they understood the purpose of the research and had given truly informed consent. Despite this, most patients participated in the hope of therapeutic benefit, although this is known to be a rare outcome in this patient subset. Trialists should be aware, and take account of the expectations that participants place in trial drugs